Kennedy Capital Management LLC Grows Holdings in ADMA Biologics Inc $ADMA

Kennedy Capital Management LLC raised its position in ADMA Biologics Inc (NASDAQ:ADMA) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 677,600 shares of the biotechnology company’s stock after buying an additional 133,427 shares during the period. Kennedy Capital Management LLC’s holdings in ADMA Biologics were worth $12,359,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Boothbay Fund Management LLC purchased a new position in ADMA Biologics in the third quarter valued at $11,334,000. Tealwood Asset Management Inc. purchased a new position in ADMA Biologics in the fourth quarter valued at $1,315,000. American Century Companies Inc. increased its stake in shares of ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after purchasing an additional 84,934 shares in the last quarter. First Light Asset Management LLC increased its stake in shares of ADMA Biologics by 12.3% during the third quarter. First Light Asset Management LLC now owns 1,069,233 shares of the biotechnology company’s stock worth $15,675,000 after purchasing an additional 117,137 shares in the last quarter. Finally, Public Sector Pension Investment Board increased its stake in shares of ADMA Biologics by 14.4% during the third quarter. Public Sector Pension Investment Board now owns 930,800 shares of the biotechnology company’s stock worth $13,646,000 after purchasing an additional 116,867 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Raymond James upgraded ADMA Biologics to moderate buy and set a $21 price target, signaling meaningful upside versus recent trading levels.
• Neutral Sentiment: Several law firms reiterated that investors in ADMA Biologics can seek lead-plaintiff status in the already filed class action, with the deadline set for August 10, 2026. Article Title
• Neutral Sentiment: The company continues to face a broad set of investor-rights notices and duplicate lawsuit solicitations from firms including Rosen, Kirby McInerney, Faruqi & Faruqi, and others, keeping the stock in litigation-focused headlines. Article Title
• Negative Sentiment: Multiple class actions allege ADMA Biologics misrepresented its operations and revenue quality, including channel-stuffing claims and internal-control issues, which raises legal and reputational risk for shareholders.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 3.90% of the stock is owned by company insiders.

ADMA Biologics Stock Performance

ADMA opened at $8.21 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The company’s 50 day simple moving average is $9.17 and its two-hundred day simple moving average is $14.12. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $21.53. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 12.07 and a beta of 0.73.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same period last year, the company posted $0.11 EPS. The business’s revenue was down .3% on a year-over-year basis. Analysts expect that ADMA Biologics Inc will post 0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ADMA shares. Raymond James Financial started coverage on shares of ADMA Biologics in a research note on Wednesday. They set an “outperform” rating and a $21.00 target price for the company. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Canaccord Genuity Group cut their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.